A patient who had required insulin for 18 years discontinued treatment following removal of a giant noradrenergic pheochromocytoma, with glycated hemoglobin decreasing from 8.9% to between 5.9% and 6.1% without antidiabetic medications. Severe, prolonged insulin-requiring diabetes associated with predominantly norepinephrine-secreting tumors may be reversible, challenging conventional assumptions about their metabolic effects.
Researchers described a 37-year-old male patient with a body mass index (BMI) of 23.7 kg/m² who had been diagnosed with presumed type 1 diabetes at 19 years and subsequently developed hypertension. Following presentation with abdominal pain and urinary abnormalities, imaging identified a right adrenal mass measuring 10.1 × 8.0 × 6.7 cm. Biochemical testing revealed urinary normetanephrine exceeding 5,000 μg/24 hours, with urinary metanephrine remaining within the reference range, indicating a predominantly noradrenergic secretory profile. The patient underwent right adrenalectomy and nephrectomy, with histopathologic examination confirming an intra-adrenal pheochromocytoma.
The researchers evaluated postoperative insulin requirements, glycated hemoglobin, catecholamine metabolites, and blood pressure. Additional testing included fasting C-peptide and antiglutamic acid decarboxylase antibodies to assess endogenous insulin secretion and possible autoimmune beta-cell destruction. The central clinical finding was discontinuation of insulin therapy, accompanied by improved glycemic control and resolution of hypertension.
Prior to surgery, the patient required 62 units of insulin daily, equivalent to 0.83 units/kg/day, and had a glycated hemoglobin level of 8.9%. Following tumor removal, insulin requirements declined, and treatment was eventually discontinued. During follow-up, glycated hemoglobin remained between 5.9% and 6.1% without antidiabetic medication.
Postoperative testing demonstrated a fasting C-peptide concentration of 2.58 ng/mL and negative antiglutamic acid decarboxylase antibodies. Plasma metanephrine and normetanephrine concentrations were within their respective reference ranges. The findings supported preserved endogenous insulin secretion and suggested the patient's longstanding hyperglycemia reflected a reversible metabolic disturbance rather than irreversible beta-cell destruction.
Hypertension resolved within 1 month postsurgery, allowing discontinuation of antihypertensive medication. However, the postoperative course was complicated by life-threatening hypoglycemia and hemodynamic instability. The patient had not received preoperative endocrinology consultation or recommended alpha-adrenergic blockade. The researchers attributed the hypoglycemic episodes to the abrupt reversal of catecholamine-mediated suppression of insulin secretion and insulin resistance, combined with continued exogenous insulin administration.
Severe diabetes has traditionally been associated more strongly with adrenergic pheochromocytomas, in which epinephrine inhibits pancreatic beta-cell insulin secretion. Predominantly noradrenergic tumors have generally been considered to have less pronounced metabolic effects. The researchers proposed that prolonged exposure to exceptionally high norepinephrine concentrations contributed to both insulin resistance and functional beta-cell suppression.
The tumor's size, exceeding 10 cm, and elevated catecholamine concentrations suggested that total hormonal burden and duration of exposure may influence metabolic severity beyond the tumor's secretory profile alone. The patient's insulin requirement suggested that insulin resistance was unlikely to be the sole mechanism.
The report was limited to 1 patient, preventing generalization to other patients with noradrenergic pheochromocytomas. Preoperative C-peptide measurements and direct assessments of insulin sensitivity were unavailable, limiting confirmation of the proposed metabolic mechanism. Germline genetic testing, including evaluation of SDHB, SDHD, and VHL, was not performed. The total duration of postoperative follow-up was not clearly specified.
Prolonged norepinephrine excess may produce severe but potentially reversible insulin-requiring diabetes, even following years of treatment. They also highlight the importance of considering secondary causes of diabetes in patients with atypical clinical presentations and hypertension. “Our observation challenges this dichotomy,” wrote lead study author Luiz F. Viola, of the Department of Endocrinology, Diabetes, and Nutrition at NOVO Hospital in France, and colleagues.
The study authors reported no conflicts of interest.
Source: JCEM Case Reports
